Search
Bismuth subsalicylate
go.drugbank.com/drugs/DB01294ApprovedVet approved[A230728] It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract. … [L32318] Bismuth subsalicylate is a component of HELIDAC Therapy (bismuth subsalicylate, [metronidazole], and [tetracycline]), which is a treatment regimen indicated for the eradication of _H. pylori_
Synonyms: 2-Hydroxy-benzo[1,3,2]dioxabismin-4-oneProducts: Kao-tin Peppermint Flavor, BISMUCAR®Inotersen
go.drugbank.com/drugs/DB14713ApprovedInvestigationalInotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. … It was FDA approved in October 2018.
Propafenone
go.drugbank.com/drugs/DB01182ApprovedInvestigationalAn antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IcSynonyms: 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone, 2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenoneEculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigationalEculizumab is a monoclonal antibody that targets complement protein C5. … [L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria
Products: SOLIRIS ® 300 MGSOLUCION PARA INFUSIÓN INTRAVENOSA, ELIZARIA® 10MG/ML SOLUCIÓN CONCENTRADA PARA INFUSIÓNOpicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine … Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsDelgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingSynonyms: 3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile, 1,6-DIAZASPIRO(3.4)OCTANE-1-PROPANENITRILE, 3-METHYL-.BETA.-OXO-6-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (3S,4R)-Polysorbate 20
go.drugbank.com/drugs/DB11178ApprovedPolysorbate 20 is a wetting agent in food products, as well as washing agent, stabilizer and solubilizer in labratory assays and industrial applications. … Polysorbate 20 is a polysorbate-type nonionic surfactant used in many commercial, household and pharmaceutical products. It is composed of 20 repeated units of polyethylene glycol via ethoxylation.
Categories: Compounds used in a research, industrial, or household setting, P-glycoprotein inhibitorsPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexProducts: ICLUSIG® 15 MG TABLETAS RECUBIERTASTarlatamab
go.drugbank.com/drugs/DB17256ApprovedInvestigationalTarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer. … [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed
Synonyms: Immunoglobulin scfv-scfv-scfc, anti-(homo sapiens dll3 (delta-like ligand 3)) and anti-(homo sapiens cd3e (cd3 epsilon, leu-4)), monoclonal antibody single chain (scfv)2-scfc, bispecificMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … This decision was supported by findings from the phase 3 SORAYA trial (NCT04296890).[L43967,L43972] It was subsequently granted full approval in March 2024.
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates